ATHENA NEUROSCIENCES, INC.
Who We Are and What We Do
The need is real: Alzheimer's Disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, migraine, cerebral palsy and
various other lesser-known conditions all affect the human neurological system, often with devastating consequences despite
the best medical care available. It has been estimated that at any given time nearly 10% of the population is affected by
neurological disease or injury. When neurological illness strikes, the neurologist is often at the front line providing patient clinical
care. In the fight against neurological illness, Athena Neurosciences, Inc. is working to advance and improve the neurologist's
medical arsenal.
Athena, a wholly-owned subsidiary of Elan Corporation, plc, is a biopharmaceutical company headquartered in South San
Francisco, California, that discovers, develops and markets therapeutic products and diagnostic services for people with
neurological conditions.
ATHENA DIAGNOSTICS: PROVIDING NEUROLOGISTS INFORMATION TO BETTER DIAGNOSE AND
TREAT NEUROLOGICAL CONDITIONS, INCLUDING ALZHEIMER'S DISEASE
Many neurological illnesses are difficult for neurologists to diagnose and treat. Athena Diagnostics is a reference laboratory
offering physicians more than 50 different testing services that assist in clinical diagnosis and decision-making for a wide range
of neurological disorders.
Alzheimer's disease is notoriously difficult to diagnose. In March 1996, Athena Diagnostics introduced to physicians its
Alzheimer's Disease Diagnosis Service.
ATHENA RX HOME PHARMACY: PROVIDING COMPREHENSIVE PHARMACY SERVICES TO PEOPLE
WITH NEUROLOGICAL CONDITIONS
Athena Rx Home Pharmacy is a full-service, express delivery pharmacy specifically designed to serve the needs of people with
neurological disorders.
ATHENA'S RESEARCH: WORKING TO DISCOVER NEW TREATMENTS FOR NEUROLOGICAL
DISEASES
Athena and its corporate partners have established leading research programs that aim to discover new treatments for
Alzheimer's disease, multiple sclerosis and other neurological diseases.
Athena, in collaboration with Eli Lilly and Company, has made significant advances in Alzheimer's disease research. The
development of a proprietary transgenic mouse model for Alzheimer's disease should enable Athena researchers to screen for
potential therapies for the disease. Athena's Alzheimer's disease research program focuses on the role of a protein known as
beta-amyloid peptide, the main constituent of plaque deposits found in the Alzheimer's brain. Athena scientists believe that
beta-amyloid peptide plays a central role in the Alzheimer's disease process, and they are working to identify compounds that
either inhibit beta-amyloid peptide production or mitigate its effects.
DEVELOPING NEW THERAPIES THAT BENEFIT PEOPLE WITH NEUROLOGICAL CONDITIONS
Athena is currently conducting clinical trials with new drug therapies for multiple sclerosis, cervical dystonia, epileptic seizures
and spasticity associated with multiple sclerosis or spinal cord injury. The U.S. Food and Drug Administration has, in recent
months, approved two Athena products, Zanaflex and Diastat. Additionally, a new diagnostic test NAbFeron has been added
in the Diagnostics Division.
WHERE WE ARE LOCATED
Corporate Headquarters
Athena Neurosciences, Inc.
800 Gateway Boulevard
South San Francisco, California 94080
Telephone: 650-877-0900
Fax: 650-877-8370
E-mail:calmonte@msn.com
Athena Rx Home Pharmacy
800 Gateway Boulevard
South San Francisco, California 94080
Telephone: 800-5ATHENA (800-528-4362)
Fax: 650-877-7433
Athena Diagnostics, Inc.*
Four Biotech Park
377 Plantation Street
Worcester, MA 01605
Telephone: 508-756-2886
Telephone: 800-394-4493
Fax: 508-753-5601
Athena Neurosciences (Europe) Ltd.*
1 Meadway Court
Rutherford Close
Stevenage, Herts SG1 2EF
United Kingdom
Telephone: 44-1438-730200
Fax: 44-1438-741452
*wholly-owned subsidiaries of Athena Neurosciences, Inc. |
